These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 4187313)

  • 1. Mechanisms of electroencephalographic and behavioral changes produced by parenteral L-DOPA.
    Harner RN; Dorman RM
    Electroencephalogr Clin Neurophysiol; 1969 Sep; 27(7):672. PubMed ID: 4187313
    [No Abstract]   [Full Text] [Related]  

  • 2. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 3. Side effects of L-dopa treatment.
    Greenburg J
    Pa Med; 1971 Apr; 74(4):55-6. PubMed ID: 5147645
    [No Abstract]   [Full Text] [Related]  

  • 4. L-dopa for parkinsonism.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
    [No Abstract]   [Full Text] [Related]  

  • 5. L-dopa. II.
    Br Med J; 1970 Nov; 4(5734):541-2. PubMed ID: 4099003
    [No Abstract]   [Full Text] [Related]  

  • 6. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 7. [Side effects occurring in the course of treatment of parkinsonism with L-dopa].
    Kuran W
    Neurol Neurochir Pol; 1973; 7(4):587-94. PubMed ID: 4583001
    [No Abstract]   [Full Text] [Related]  

  • 8. Involvement of 5-hydroxytryptamine in the cortical synchronization induced by L-DOPA in the rabbit.
    Gaillard JM; Bartholini G; Herkert B; Tissot R
    Brain Res; 1974 Mar; 68(2):344-50. PubMed ID: 4275029
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential analysis: manganese, catecholamines and L-dopa induced dyskinesia.
    Papavasiliou PS; Miller ST; Cotzias GC; Kraner HW; Hsieh RS
    J Neurochem; 1975 Sep; 25(3):215-9. PubMed ID: 1159419
    [No Abstract]   [Full Text] [Related]  

  • 11. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 12. Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
    Barbeau A
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534982
    [No Abstract]   [Full Text] [Related]  

  • 13. [Abnormal movements observed during treatment of Parkinson's disease with L-dopa].
    Sigwald J; Raymondeaud C
    Rev Neurol (Paris); 1970 Feb; 122(2):103-12. PubMed ID: 4397165
    [No Abstract]   [Full Text] [Related]  

  • 14. [Abnormal movements induced by L-Dopa and dopamine metabolism disorders].
    Lhermitte F; Rosa A; Comoy E; Bohuon C
    Rev Neurol (Paris); 1973 Dec; 129(6):313-24. PubMed ID: 4794176
    [No Abstract]   [Full Text] [Related]  

  • 15. Electroencephalographic changes occurring during L-dopa treatment.
    Herman MN; Rowan AJ; Goldensohn ES
    Trans Am Neurol Assoc; 1971; 96():252-4. PubMed ID: 5159096
    [No Abstract]   [Full Text] [Related]  

  • 16. L-Dopa treatment in Parkinson's Disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
    [No Abstract]   [Full Text] [Related]  

  • 17. [Electroencephalographic and behavioral study of monkeys under the influence of LSD 25].
    Chatelier G; Borenstein P
    Therapie; 1968; 23(6):1289-98. PubMed ID: 4976954
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa.
    Godwin-Austen RB; Bergmann S; Frears CC
    Br Med J; 1971 Nov; 4(5786):522-4. PubMed ID: 4942463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-dopa induced dyskinesias in 152 patients with Parkinson's disease.
    Mones RJ; Elizan TS; Siegel G
    Trans Am Neurol Assoc; 1970; 95():286-7. PubMed ID: 5514393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.